title: Levels of VEGF but not VEGF(165b) are increased in the vitreous of patients with retinal vein occlusion.
abstract: OBJECTIVE
  To determine the concentration of the pro-angiogenic vascular endothelial growth factor VEGF(165) (VEGF) and the anti-angiogenic VEGF(165b) in vitreous samples of patients with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) in comparison to patients without retinal occlusive disease.
  
  
  METHODS
  Experimental laboratory investigation.
  
  
  METHODS
  Vitreous samples were collected from patients undergoing surgery for arteriovenous dissection after BRVO, radial optic neurotomy after CRVO in the occlusion group, or macular pucker or macular hole in the control group. Concentrations of VEGF and VEGF(165b) were determined by ELISA and an ELISA-type antibody microarray.
  
  
  RESULTS
  Average vitreal concentration of VEGF was 8.6 ng/mL in the CRVO group and 2.0 ng/mL in the BRVO group as compared to 0.26 ng/mL in the control group. Average vitreal concentration of VEGF(165b) was 27 pg/mL in the CRVO group, 42 pg/mL in the BRVO group, and 49 pg/mL in the control group. In patients with CRVO and BRVO, the angiogenic balance was shifted towards angiogenic stimulation.
  
  
  CONCLUSIONS
  The severity of RVO from BRVO to CRVO correlates with an increase of VEGF and the decrease of VEGF(165b), indicating a pro-angiogenic shift. Altering the ratio of VEGF(165b)/VEGF(165) might be a feasible approach for treating retinal occlusive diseases.
authors.affiliation: Augenklinik, Universitätsklinikum Freiburg, Freiburg, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Ehlken
authors.forename: Emma S
authors.initials: ES
authors.lastname: Rennel
authors.forename: Daniel
authors.initials: D
authors.lastname: Michels
authors.forename: Bastian
authors.initials: B
authors.lastname: Grundel
authors.forename: Amelie
authors.initials: A
authors.lastname: Pielen
authors.forename: Bernd
authors.initials: B
authors.lastname: Junker
authors.forename: Andreas
authors.initials: A
authors.lastname: Stahl
authors.forename: Lutz L
authors.initials: LL
authors.lastname: Hansen
authors.forename: Nicolas
authors.initials: N
authors.lastname: Feltgen
authors.forename: Hansjürgen T
authors.initials: HT
authors.lastname: Agostini
authors.forename: Gottfried
authors.initials: G
authors.lastname: Martin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000378:metabolism* / Q000601:surgery; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*; D014792:Visual Acuity / Q000502:physiology; D014821:Vitrectomy; D014822:Vitreous Body / Q000378:metabolism*
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A